_256_384.jpg)
Drug Approval | April 14, 2024
Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations
This facility manufactures APIs & formulations of oncology and non-oncology products.
This facility manufactures APIs & formulations of oncology and non-oncology products.
Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023
Pantoprazole Sodium Delayed-Release Tablets are indicated for short-term treatment of Erosive Esophagitis associated with GERD
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
Granules India received approval from Brazilian Health Regulatory Agency ANVISA
API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24
The inspection was conducted at Granules Pharmaceuticals Inc. (GPI) from July 31, 2023 to August 03, 2023
This product will be launched through Granules Consumer Health (GCH) division
Subscribe To Our Newsletter & Stay Updated
